Local
IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a Potential Best-in-Class DLL3 TOP1 ADC, in Neuroendocrine Carcinomas
Meet in Common connects news with real conversations. Use ThinkMatch to arrange a Roundtable and meet people to discuss this story.
Roundtables are designed for groups of four, with a shared subject and room for everyone to speak. Come for discussion, with no dating expectation.
Source: Clearwater Tribune

Single-arm extension cohort of approximately 90 refractory GEP-NEC patients to support potential accelerated approval, with ORR by BICR as the primary endpointRandomized Phase 3 trial in multiple refractory NEC subtypes, including GEP-NEC and LC-NEC, is planned to support full approval,…
This excerpt comes from the named source. Read the original for the full reporting.
Read the original at Clearwater Tribune



